Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q3 2024 Earnings Conference
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q3 2024 Earnings Conference
Administrative expenses decreased by 11% due to reduced general and administrative expenses and professional fees.The following is a summary of the Theralase Technologies Inc. (TLTFF) Q3 2024 Earnings Call Transcript:
以下是Theralase Technologies Inc. (TLTFF) 2024年第三季度業績會議通話摘要：
Financial Performance:
財務表現：
Theralase Technologies Inc. reported a revenue decrease for the nine-month period of 2024, totaling CAD622,984, which is a 12% decrease compared to the previous year.
The gross margin percentage has decreased year-over-year to 47% due to increased material costs.
Administrative expenses decreased by 11% due to reduced general and administrative expenses and professional fees.
There was a 7% year-over-year reduction in net loss for 2024, with the drug division representing 84% of this loss.
Theralase Technologies Inc.報告了截至2024年九個月的營業收入下降，總計622,984加元，較去年同期減少12%。
毛利率百分比由於材料成本上升而同比下降至47%。
由於一般和行政費用以及專業費用減少，管理費用同比減少11%。
2024年，淨虧損同比減少7%，其中藥物部門佔此虧損的84%。
Business Progress:
業務進展：
Theralase is focusing on expanding enrollment in their Phase II bladder cancer study and expects to add up to five new clinical study sites in late 2024 to early 2025.
The company has also initiated preparations to commence Phase I clinical studies for brain, lung, and blood-based cancers in 2025.
Plans for a topical ointment for herpes simplex lesions and a vaccine for avian influenza are underway.
Theralase 正專注於擴大他們第二期膀胱癌研究的招生，預計將在2024年底至2025年初增加最多五個新的臨床研究點。
公司還已啓動準備工作，計劃於2025年開始對大腦、肺部和血液性癌症進行I期臨床研究。
計劃開發用於單純皰疹病變的局部軟膏，以及用於禽流感的疫苗正在進行中。
Opportunities:
機會：
Theralase is leveraging data from Phase II bladder cancer clinical studies for potential FDA and Health Canada regulatory marketing approval.
The company aims for strategic partnership opportunities after the potential approval to aid in commercializing their next standard-of-care treatment for bladder cancer.
Potential opportunities for expanding into treatments for brain cancer, lung cancer, and blood cancers leveraging the growth in global markets for these diseases.
Theralase正在利用II期膀胱癌臨床研究的數據，以獲得潛在的FDA和加拿大衛生部門的監管營銷批准。
該公司旨在在潛在批准後尋求戰略伙伴關係機會，以協助商業化他們下一個用於膀胱癌的標準治療。
利用全球市場上這些疾病增長的潛力，公司有可能擴展到治療大腦癌、肺癌和血液癌症。
Risks:
風險：
Theralase anticipates a need for significant funding to complete its ongoing and planned clinical studies, with an estimated cost of CAD15 million to CAD30 million for the Phase II bladder cancer clinical study alone.
Regulatory risks related to obtaining necessary approvals from Health Canada and the FDA for their products are also present.
Theralase預計需要大量資金來完成其正在進行和計劃中的臨床研究，僅II期膀胱癌臨床研究的預計費用爲1500萬加元至3000萬加元。
獲得來自加拿大衛生部和美國食品藥品管理局對其產品的必要批准涉及的監管風險也存在。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
